Publicacions (34) Publicacions de Diana Isabel Llopiz Khatchikian

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination

    Frontiers in Immunology, Vol. 13

  2. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer

    Frontiers in Immunology, Vol. 13

  3. Neoantigens as potential vaccines in hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 2

  4. Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

    OncoImmunology, Vol. 11, Núm. 1

  5. The role of dendritic cells in the immune niche of the peritoneum

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 1-14

  6. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?

    International Journal of Molecular Sciences, Vol. 23, Núm. 4

2021

  1. A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets

    Journal of Personalized Medicine, Vol. 11, Núm. 6

  2. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy

    Cancer Letters, Vol. 499, pp. 279-289

  3. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

2020

  1. Cold‐inducible rna binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 11, pp. 1-18

2019

  1. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model

    Cancer Immunology, Immunotherapy, Vol. 68, Núm. 3, pp. 379-393

  2. ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity

    Molecular Therapy, Vol. 27, Núm. 11, pp. 1878-1891

  3. When cancer vaccines go viral

    Clinical Cancer Research, Vol. 25, Núm. 16, pp. 4871-4873

2018

  1. Enhancement of antitumor vaccination by targeting dendritic cell-related IL-10

    Frontiers in Immunology

  2. The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer

    OncoImmunology, Vol. 7, Núm. 4

2017

  1. Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor

    Oncotarget, Vol. 8, Núm. 42, pp. 71709-71724

  2. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination

    Oncotarget, Vol. 8, Núm. 2, pp. 2659-2671

  3. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

    Cell Reports, Vol. 20, Núm. 8, pp. 1818-1829

2016

  1. Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination

    OncoImmunology, Vol. 5, Núm. 2